[Use of thymodepressin for treating autoimmune cytopenia].
OBJECTIVE
To study influence of thymodepressin on the course of autoimmune cytopenia.


METHODS
Thymodepressin is a new synthetic hemoregulatory dipeptide (gamma-D-Glu-D-Trp). It was used for the treatment of 22 patients with autoimmune cytopenia.


RESULTS
Hemoglobin levels were elevated in autoimmune hemolytic anemia and platelet levels were high in idiopathic thrombocytopenic purpura. A thymodepressin course resulted in a fall of total lymphocyte count and activated CD3+CD69+ lymphocytes.


CONCLUSIONS
The above results, safety, absence of toxicity and allergenicity, parenteral and intranasal useability open perspectives for further studies of therapeutic action of thymodepressin as an immunodepressant in autoimmune processes.
D000328:Adult; D000368:Aged; D000743:Anemia, Hemolytic / Q000188:drug therapy*; D015703:Antigens, CD / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D037181:Lectins, C-Type; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D037181:Lectins, C-Type; D010455:Peptides; D000099192:CD69 Antigens; C449663:thymodepressin
Primenenie timodepressinoa dlia lecheniia autoimmunnykh tsitopeniĭ.